Scinai Immunotherapeutics (SCNI) Accumulated Expenses (2015 - 2026)

Scinai Immunotherapeutics has reported Accumulated Expenses for 12 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Accumulated Expenses changed N/A year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (changed N/A YoY) and the FY2025 annual result came in at $849000.0, up 61.1% from the prior year.
• Accumulated Expenses advanced to $1.6 million in Q1 2026 per SCNI's latest filing, from $849000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $1.6 million in Q1 2026 and troughed at $461000.0 in Q4 2023.
• A 5-year average of $770600.0 and a median of $650000.0 in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses tumbled 99.97% in 2022, then jumped 61.1% in 2025.
• Over 5 years, Accumulated Expenses stood at $756000.0 in 2022, then slumped by 39.02% to $461000.0 in 2023, then increased by 14.32% to $527000.0 in 2024, then soared by 61.1% to $849000.0 in 2025, then surged by 82.8% to $1.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.6 million, $849000.0, and $964000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.